Alexander Muik

8.6k total citations · 4 hit papers
41 papers, 1.9k citations indexed

About

Alexander Muik is a scholar working on Infectious Diseases, Genetics and Oncology. According to data from OpenAlex, Alexander Muik has authored 41 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Infectious Diseases, 15 papers in Genetics and 12 papers in Oncology. Recurrent topics in Alexander Muik's work include SARS-CoV-2 and COVID-19 Research (17 papers), Virus-based gene therapy research (15 papers) and CAR-T cell therapy research (11 papers). Alexander Muik is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (17 papers), Virus-based gene therapy research (15 papers) and CAR-T cell therapy research (11 papers). Alexander Muik collaborates with scholars based in Germany, United States and Austria. Alexander Muik's co-authors include Uğur Şahin, Özlem Türeci, Kena A. Swanson, Hui Cai, Ann-Kathrin Wallisch, Philip R. Dormitzer, Dorotheé von Laer, Bianca Sänger, Wei Chen and Daniel Maurus and has published in prestigious journals such as Nature, Science and Nature Communications.

In The Last Decade

Alexander Muik

35 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

2021 333 citations Alexander Muik, Ann-Kathrin Wallisch et al. Science profile →
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

2022 224 citations Alexander Muik, Bonny Gaby Lui et al. Science profile →
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

2021 212 citations Jianying Liu, Yang Liu et al. Nature profile →
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines

2022 133 citations Jeremy P. Kamil, Alexander Muik et al. profile →

Peers

Countries citing papers authored by Alexander Muik

Since Specialization

Citations

This map shows the geographic impact of Alexander Muik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Muik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Muik more than expected).

Fields of papers citing papers by Alexander Muik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Muik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Muik. The network helps show where Alexander Muik may publish in the future.

Co-authorship network of co-authors of Alexander Muik

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Muik. A scholar is included among the top collaborators of Alexander Muik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Muik. Alexander Muik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine 2024 ·Vaccine ·Shanti Pather, (unknown), (unknown), (unknown), Andrew Finlayson, (unknown), Alexander Muik, Claudia Lindemann, (unknown), Sultan Abdul-Jawad, Emily Smith, Marc Gurwith, Robert T. Chen	1
2	Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1 2024 ·Cell Reports ·Alexander Muik, Jasmin Quandt, Bonny Gaby Lui, Maren Bacher, (unknown), (unknown), Aras Toker, (unknown), Orkun Ozhelvaci, (unknown), Svetlana Shpyro, Isabel Vogler, (unknown), Özlem Türeci, Uğur Şahin	0
3	1072P DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models 2023 ·Annals of Oncology ·(unknown), Andreea Ioan‐Facsinay, Andrea Imle, (unknown), (unknown), Lars Guelen, (unknown), Mischa Houtkamp, Aras Toker, Saskia M. Burm, Joshua T. Gamse, (unknown), David Satijn, Alexander Muik, Tahamtan Ahmadi, Özlem Türeci, Kristel Kemper, Uğur Şahin, Esther C.W. Breij	0
4	Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era 2023 ·Expert Review of Vaccines ·Shanti Pather, Alexander Muik, (unknown), Federico Mensa	11
5	Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines 2023 ·Vaccines ·Cynthia M. Rohde, Claudia Lindemann, (unknown), Rani S. Sellers, Jan Diekmann, Shambhunath Choudhary, Lila Ramaiah, Annette B. Vogel, Yana Chervona, Alexander Muik, Uğur Şahin	17
6	SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines 2023 ·Frontiers in Immunology ·Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, Paul Moss, Jeremy P. Kamil, Sandra Ciesek, Alexander Muik, Özlem Türeci	35
7	Early computational detection of potential high-risk SARS-CoV-2 variants 2023 ·Computers in Biology and Medicine ·Karim Beguir, Marcin J. Skwark, Yunguan Fu, Thomas Pierrot, Nicolás López Carranza, (unknown), (unknown), (unknown), (unknown), Bonny Gaby Lui, Bianca Sänger, Yunpeng Liu, Asaf Poran, Alexander Muik, Uğur Şahin	19
8	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine 2022 ·Nature Communications ·Chaitanya Kurhade, Jing Zou, Hongjie Xia, Hui Cai, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Xuping Xie, Kena A. Swanson, Pei‐Yong Shi	41
9	Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes 2022 ·Science Immunology ·Jasmin Quandt, Alexander Muik, (unknown), Bonny Gaby Lui, (unknown), (unknown), Ann-Kathrin Wallisch, Petra Adams‐Quack, Maren Bacher, Andrew Finlayson, Orkun Ozhelvaci, Isabel Vogler, Katharina Grikscheit, Sebastian Hoehl, Udo Goetsch, Sandra Ciesek, Özlem Türeci, Uğur Şahin	111
10	Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5 2022 ·Science Immunology ·Alexander Muik, Bonny Gaby Lui, Maren Bacher, Ann-Kathrin Wallisch, Aras Toker, Andrew Finlayson, (unknown), Orkun Ozhelvaci, Katharina Grikscheit, Sebastian Hoehl, Sandra Ciesek, Özlem Türeci, Uğur Şahin	45
11	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants 2022 ·npj Vaccines ·Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, Hui Cai, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Uğur Şahin, Xuping Xie, Philip R. Dormitzer, Pei‐Yong Shi	6
12	Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2 2022 ·Cell Host & Microbe ·Hongjie Xia, Jing Zou, Chaitanya Kurhade, Hui Cai, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Xuping Xie, Kena A. Swanson, Pei‐Yong Shi	64
13	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants breakdown → 2021 ·Nature ·Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, Hui Cai, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Uğur Şahin, Xuping Xie, Philip R. Dormitzer, Pei‐Yong Shi	212
14	Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera breakdown → 2021 ·Science ·Alexander Muik, Ann-Kathrin Wallisch, Bianca Sänger, Kena A. Swanson, (unknown), Wei Chen, Hui Cai, Daniel Maurus, (unknown), Özlem Türeci, Philip R. Dormitzer, Uğur Şahin	333
15	Ligand Coupling to the AAV Capsid for Cell-Specific Gene Transfer 2019 ·Methods in molecular biology ·(unknown), Alexander Muik, Christian J. Buchholz	12
16	Covalent coupling of high-affinity ligands to the surface of viral vector particles by protein trans-splicing mediates cell type-specific gene transfer 2017 ·Biomaterials ·Alexander Muik, (unknown), Thorsten Friedel, Anke Muth, K. Patricia Hartmann, Irene C. Schneider, Robert C. Münch, Christian J. Buchholz	40
17	Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors 2015 ·Nature Communications ·Robert C. Münch, Anke Muth, Alexander Muik, Thorsten Friedel, (unknown), Birgit Dreier, Alexandra Trkola, Andreas Plückthun, Hildegard Büning, Christian J. Buchholz	105
18	Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency 2014 ·Cancer Research ·Alexander Muik, Lawton J. Stubbert, (unknown), (unknown), Janine Kimpel, (unknown), Reinhard Tober, Andreas Volk, Sabine Klein, Ursula Dietrich, (unknown), Theresa Falls, Hrvoje Miletić, David F. Stojdl, John C. Bell, Dorotheé von Laer	108
19	Mature T-cell Lymphomagenesis Induced by Retroviral Insertional Activation of Janus Kinase 1 2013 ·Molecular Therapy ·(unknown), Benjamin Rengstl, Alexander Muik, Mina Petkova, (unknown), (unknown), Kathrin Warner, Giuliano Crispatzu, Martin‐Leo Hansmann, Marco Herling, Dorotheé von Laer, Sebastian Newrzela	23
20	Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy 2012 ·Journal of Molecular Medicine ·Alexander Muik, (unknown), (unknown), Andreas Volk, (unknown), Ursula Dietrich, Dorotheé von Laer	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact